Last reviewed · How we verify
NCT07166003: NeoIP-Lung
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
trial testing Pneumonectomy in Lung Cancer, Non-Small Cell in 500 participants. Currently enrolling.
2 February 2027
Quick facts
| Lead sponsor | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 20 April 2025 |
| Primary completion | 2 February 2027 |
| Estimated completion | 14 April 2030 |
| Sites | 1 location across China |
Drugs / interventions tested
- Pneumonectomy
- lobectomy
- radiotherapy — full drug profile →
- Anti-Tumor Drugs — full drug profile →
Conditions studied
- Lung Cancer, Non-Small Cell — all drugs for Lung Cancer, Non-Small Cell →
- Immunotherapy — all drugs for Immunotherapy →
Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Who can join
Adults 18 to 79, any sex, with Lung Cancer, Non-Small Cell or Immunotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn about the long-term effects of neoadjuvant immunotherapy in patients with lung cancer. The main questions it aims to answer are: * Does pneumonectomy bring more benefits for pateints than lobectomy? * Does surgery bring more benefits for patients than non-surgery modalities (such as radiotherapy) after neoadjuvnat immunotherapy? Participants will receive neoadjuvant treatment and the study will analyze the data.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07166003
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer, Non-Small Cell
Currently open trials in the same condition.
- NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
- NCT06405230 — Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Or · Phase 1, PHASE2 · recruiting
- NCT06942845 — Exploration of Risk Factors for Postoperative Cerebral Infarction in Lung Cancer Patients: a Retrospective Single-centre · active not recruiting
- NCT06687408 — Sleeve Lobectomy for Lung Cancer in Minimally Invasive Surgical Techniques · recruiting
- NCT06769295 — A Phase II Study of AK112 (PD1/VEGF Bispecific) in Combination with Chemotherapy in Patients with NSCLC · Phase 2 · recruiting
Other Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials
Trials by the same sponsor.
- NCT07531563 — Protein Supplementation for Radiation- Induced Oral Mucositis in Head and Neck Cancer Patients Receiving Radiotherapy · NA · not yet recruiting
- NCT07537049 — BR101 in Patients With Relapsed/Refractory Multiple Myeloma · Phase 1 · not yet recruiting
- NCT07187154 — The Application of Symptoms Management Program Based on the Patient Reported Outcome After Esophagectomy · NA · not yet recruiting
- NCT07530549 — A Phase II Single-arm Clinical Study in the Treatment of Locally Advanced Esophageal Cancer After Failed Neoadjuvant Che · Phase 2 · not yet recruiting
- NCT07507058 — Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07166003 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Last refreshed: 10 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07166003.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing